Tiziana Life Sciences Ltd
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Ivor R. Elrifi Ph.D.
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Park Lane London United Kingdom W1K 1NA
- IPO Date
- Nov 20, 2018
- CIK
- 0001723069
- Website
- tizianalifesciences.com
- Similar Companies
- Business
- Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Company News
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
Tiziana Life Sciences to Present at the Bio International Convention
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
Tiziana Life Sciences Announces Purchase of Shares by Chairman
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
Tiziana shares surge 21% on promising multiple sclerosis data
Tiziana reports encouraging results for nasal MS drug in early study
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Tiziana submits FDA investigational new drug application